表紙
市場調査レポート

角膜炎:パイプライン分析

Keratitis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 200462
出版日 ページ情報 英文 83 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
角膜炎:パイプライン分析 Keratitis - Pipeline Review, H1 2016
出版日: 2016年04月27日 ページ情報: 英文 83 Pages
概要

角膜炎とは角膜の炎症です。症状としては、眼の充血、眼痛、視覚低下(かすみ目)、視力低下、光に対する過敏症などが現れます。 危険因子として、ウィルス感染、けが、気候条件、免疫力の低下などが挙げられます。

当レポートでは、角膜炎の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

角膜炎 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Adamis Pharmaceuticals Corporation
  • Cellceutix Corporation
  • Dompe Farmaceutici S.p.A.
  • Kala Pharmaceuticals, Inc.
  • Peregrine Pharmaceuticals, Inc.
  • RegeneRx Biopharmaceuticals, Inc.
  • Sirnaomics, Inc.
  • The Medicines Company

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • brilacidin
  • C-31G
  • IBN-1
  • loteprednol etabonate
  • moxifloxacin hydrochloride
  • PGN-632
  • PIM-45
  • Recombinant Human Nerve Growth Factor
  • RGN-259
  • Small Molecules to Inhibit ATM for Herpes Keratitis
  • STP-601
  • targocil
  • tigecycline

最近のパイプライン動向

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7881IDB

Summary

Global Markets Direct's, 'Keratitis - Pipeline Review, H1 2016', provides an overview of the Keratitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Keratitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Keratitis
  • The report reviews pipeline therapeutics for Keratitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Keratitis therapeutics and enlists all their major and minor projects
  • The report assesses Keratitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Keratitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Keratitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Keratitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Keratitis Overview
  • Therapeutics Development
    • Pipeline Products for Keratitis - Overview
    • Pipeline Products for Keratitis - Comparative Analysis
  • Keratitis - Therapeutics under Development by Companies
  • Keratitis - Therapeutics under Investigation by Universities/Institutes
  • Keratitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Keratitis - Products under Development by Companies
  • Keratitis - Products under Investigation by Universities/Institutes
  • Keratitis - Companies Involved in Therapeutics Development
    • Adamis Pharmaceuticals Corporation
    • Cellceutix Corporation
    • Dompe Farmaceutici S.p.A.
    • NanoViricides, Inc.
    • ReceptoPharm, Inc.
    • RegeneRx Biopharmaceuticals, Inc.
    • Sirnaomics, Inc.
    • The Medicines Company
  • Keratitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • B-2088 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • brilacidin tetrahydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C-31G - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dipyridamole - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Herpecide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IBN-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JDE-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JDE-004 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PIM-45 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RGN-259 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RPI-MN - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit ATM for Herpes Keratitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STP-601 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides for Bacterial Keratitis and Wounds - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • targocil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tigecycline - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Keratitis - Recent Pipeline Updates
  • Keratitis - Dormant Projects
  • Keratitis - Product Development Milestones
    • Featured News & Press Releases
      • Jan 12, 2016: NanoViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Fransisco on Wednesday
      • Dec 02, 2015: rhNGF, the Dompe Biotech Molecule for the Treatment of Neurotrophic Keratitis, Receives Orphan Drug Designation from the European Medicines Agency
      • Oct 21, 2015: RegeneRx Updates on U.S. Ophthalmic Clinical Trials
      • Sep 30, 2015: RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial
      • Sep 21, 2015: RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy Clinical Trial with RGN-259
      • Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy
      • Sep 25, 2014: EuCornea: Dompe wins the "Best Poster Award" for its preliminary data concerning the use of rhNGF in the treatment of neurotrophic keratitis
      • Jul 23, 2014: Dompe announces the Food and Drug Administration has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis
      • Nov 04, 2013: Cellceutix to Pursue Significant Conjuctivitis and Kerititis Ocular Markets With Novel Antibiotic Brilacidin
      • Feb 14, 2013: Dompe Announces Enrollment Of First Patient In First International Clinical Trial Of rhNGF For Treatment Of Neurotrophic Keratitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Keratitis, H1 2016
  • Number of Products under Development for Keratitis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Keratitis - Pipeline by Adamis Pharmaceuticals Corporation, H1 2016
  • Keratitis - Pipeline by Cellceutix Corporation, H1 2016
  • Keratitis - Pipeline by Dompe Farmaceutici S.p.A., H1 2016
  • Keratitis - Pipeline by NanoViricides, Inc., H1 2016
  • Keratitis - Pipeline by ReceptoPharm, Inc., H1 2016
  • Keratitis - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2016
  • Keratitis - Pipeline by Sirnaomics, Inc., H1 2016
  • Keratitis - Pipeline by The Medicines Company, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Keratitis Therapeutics - Recent Pipeline Updates, H1 2016
  • Keratitis - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Keratitis, H1 2016
  • Number of Products under Development for Keratitis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top